Logo
x

Search category

Subscribe Now

Report

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis

  • October 25, 2021
Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19

Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19

  • October 25, 2021
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III Trial for the Treatment of Eosinophilic Esophagitis

  • October 25, 2021
Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19

Merck and Ridgeback Report the Initiation of EMA Rolling Review of Molnupiravir for the Treatment of COVID-19

  • October 25, 2021
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

  • October 22, 2021
Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III PRIME2 Trial for the Treatment of Prurigo Nodularis

  • October 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.